Gritstone bio, Inc. (GRTS) has a consensus analyst rating of Buy, based on 13 analysts covering the stock. Of those, 7 recommend buying, 4 recommend holding, and 2 recommend selling.
The analyst consensus price target for GRTS is $4.67, representing a +14,403.1% upside from the current price of $0.0322. Price targets range from a low of $3.00 to a high of $6.00.
